Pulmonary arterial hypertension (PAH) is a rare condition that's difficult to treat. The hallmarks of the disease—narrowing ...

Adults with pulmonary arterial hypertension using vs. not using GLP-1 receptor agonists had significantly lower relative ...

Adding sotatercept to standard therapy within a year of diagnosis lowers the risk for clinical worsening in patients with ...

In pulmonary arterial hypertension, GLP-1 receptor agonists significantly lowered the risk of right heart failure compared ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from ...

Sotatercept (Winrevair) represents the first new mechanism of action for pulmonary arterial hypertension (PAH) treatment in over a decade, offering hope for patients with this life-threatening ...

Benefit with sotatercept seen among adults with pulmonary arterial hypertension diagnosed less than a year earlier.

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. This is something I'm particularly ...

Because PAH is progressive, ongoing risk assessment is an essential part of PAH management. Once diagnosed, the overall treatment goal for people with PAH is to achieve and maintain a low-risk status ...

Pulmonary hypertension is traditionally defined as a mean pulmonary artery pressure of ≥25 mmHg when a patient is at rest, though a mean pressure of >20 mm Hg is considered to be abnormal and may ...

The U.S. Food and Drug Administration (FDA) approved sotatercept in March 2024 for treatment of pulmonary hypertension, according to the drug’s maker Merck. The drug is sold under the brand name ...

A new study published in The New England Journal of Medicine showed that within a year after being diagnosed with pulmonary ...